Advocating for Kratom's Schedule I classification emphasizes public health protection.  Key concerns include its potential for abuse, similarity to controlled substances, and the lack of FDA-approved research confirming safety and effectiveness.  Scheduling kratom would enhance regulatory control, ensuring any therapeutic claims are scientifically validated.  This approach aims to safeguard consumers from unproven treatments and align with efforts to maintain public health standards.